NeuroOne Medical Technologies (NMTC) Projected to Post Earnings on Tuesday

NeuroOne Medical Technologies (NASDAQ:NMTC) is expected to be releasing its Q2 2026 results before the market opens on Tuesday, May 12th. Analysts expect NeuroOne Medical Technologies to post earnings of ($0.2267) per share and revenue of $2.5780 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:30 AM ET.

NeuroOne Medical Technologies (NASDAQ:NMTC) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.06. The company had revenue of $2.89 million during the quarter, compared to analyst estimates of $2.47 million. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%. On average, analysts expect NeuroOne Medical Technologies to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

NeuroOne Medical Technologies Trading Up 1.3%

NeuroOne Medical Technologies stock traded up $0.06 during mid-day trading on Tuesday, hitting $4.55. The company’s stock had a trading volume of 2,016 shares, compared to its average volume of 43,938. The firm has a market capitalization of $38.32 million, a PE ratio of -4.46 and a beta of 0.60. NeuroOne Medical Technologies has a 1 year low of $3.27 and a 1 year high of $6.96. The stock’s fifty day moving average is $4.51 and its two-hundred day moving average is $4.58.

Insider Transactions at NeuroOne Medical Technologies

In related news, insider David J. Wambeke bought 166,666 shares of the firm’s stock in a transaction that occurred on Sunday, March 1st. The stock was purchased at an average cost of $4.02 per share, for a total transaction of $669,997.32. Following the completion of the acquisition, the insider owned 166,666 shares in the company, valued at approximately $669,997.32. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 2,438 shares of company stock valued at $11,702 in the last ninety days. Company insiders own 11.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NMTC. Squarepoint Ops LLC acquired a new stake in NeuroOne Medical Technologies in the fourth quarter valued at $36,000. Susquehanna International Group LLP acquired a new stake in NeuroOne Medical Technologies in the third quarter valued at $47,000. XTX Topco Ltd raised its stake in NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after buying an additional 65,163 shares in the last quarter. Renaissance Technologies LLC raised its stake in NeuroOne Medical Technologies by 10.2% in the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after buying an additional 70,428 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in NeuroOne Medical Technologies in the first quarter valued at $84,000. 16.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

NMTC has been the subject of several research analyst reports. Zacks Research lowered NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 13th. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. Finally, JonesTrading assumed coverage on NeuroOne Medical Technologies in a report on Monday, March 2nd. They issued a “buy” rating and a $9.00 target price for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $13.50.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.